Skip to content
10-K

Annual Report

Aptose Biosciences Inc. APTOF

0001193125-26-135012

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 31, 2026 2.55M sh
Shares Diluted FY 2025 · Dec 31, 2025 2.45M sh
Shares Diluted FY 2025 · Dec 31, 2024 698.98K sh
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $5K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$21.99M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$35.98M
Cash And Equivalents FY 2025 · Dec 31, 2025 $935K
Cash And Equivalents FY 2025 · Dec 31, 2024 $6.15M
Stockholders Equity FY 2025 · Dec 31, 2025 −$27.17M
Stockholders Equity FY 2025 · Dec 31, 2024 −$4.54M
Stockholders Equity FY 2025 · Dec 31, 2023 −$2.9M
Current Liabilities FY 2025 · Dec 31, 2025 $9.31M
Current Liabilities FY 2025 · Dec 31, 2024 $4.46M
Total Liabilities FY 2025 · Dec 31, 2025 $37.18M
Total Liabilities FY 2025 · Dec 31, 2024 $14.67M
Current Assets FY 2025 · Dec 31, 2025 $6.45M
Current Assets FY 2025 · Dec 31, 2024 $9.53M
Total Assets FY 2025 · Dec 31, 2025 $10.01M
Total Assets FY 2025 · Dec 31, 2024 $10.13M
Eps Diluted FY 2025 · Dec 31, 2025 −$10.41
Eps Diluted FY 2025 · Dec 31, 2024 −$36.38
Eps Basic FY 2025 · Dec 31, 2025 −$10.41
Eps Basic FY 2025 · Dec 31, 2024 −$36.38
Sga Expense FY 2025 · Dec 31, 2025 $13.38M
Sga Expense FY 2025 · Dec 31, 2024 $11.15M
Rd Expense FY 2025 · Dec 31, 2025 $11.34M
Rd Expense FY 2025 · Dec 31, 2024 $15.1M
Net Income FY 2025 · Dec 31, 2025 −$25.47M
Net Income FY 2025 · Dec 31, 2024 −$25.43M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $0